Understanding the Patient Experience in Progesterone Management for Endometrial Cancer and Complex Atypical Hyperplasia

Overview

About this study

The purpose of this study is to gain a deeper understanding of the specific patient experience for women undergoing progesterone management for early-stage endometrial cancer and complex atypical hyperplasia due to morbid obesity (BMI ≥ 40).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Biopsy confirmed Grade 1-2 endometrioid endometrial cancer or complex atypical hyperplasia.
No major surgery within 3 months of diagnosis.
Diagnosis in the last 10 years.
BMI ≥ 40 kg/m^2.
English speaking.

Exclusion Criteria:

Non-English speaking.
Advanced stage endometrial cancer or histology other than endometrioid.

Eligibility last updated 5/13/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Carrie Langstraat, M.D.	Open for enrollment	Contact information: Aparna Kailasam M.D. (507) 266-9473 Kailasam.Aparna@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Carrie Langstraat, M.D.

Open for enrollment

Contact information:

Aparna Kailasam M.D.

(507) 266-9473

Kailasam.Aparna@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials